Synonyms: compound 17k [PMID 20420387] | GSK-1070916
Compound class:
Synthetic organic
Comment: GSK1070916 is reported to be an ATP-competitive, potent and selective inhibitor of Aurora kinases B and C [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
One Phase 1 clinical trial assessing GSK1070916 in patients with advanced solid tumors has been completed (see NCT01118611). |
Mechanism Of Action and Pharmacodynamic Effects |
The Aurora kinases are essential components involved in the regulation of mitosis [2]. These enzymes are frequently overexpressed or amplified in human tumours. Small molecule Aurora kinase inhibitors are therefore being sought as cancer chemotherapeutics [3-4]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01118611 | Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors | Phase 1 Interventional | Cancer Research UK |